Wendell David Associates Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, HoldingsChannel reports. The fund owned 118,794 shares of the company’s stock after selling 711 shares during the period. Johnson & Johnson makes up approximately 2.8% of Wendell David Associates Inc.’s holdings, making the stock its 9th biggest holding. Wendell David Associates Inc.’s holdings in Johnson & Johnson were worth $15,330,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Stuart Chaussee & Associates Inc. raised its position in shares of Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares in the last quarter. Deane Retirement Strategies Inc. raised its position in shares of Johnson & Johnson by 0.7% in the 4th quarter. Deane Retirement Strategies Inc. now owns 12,458 shares of the company’s stock valued at $1,608,000 after purchasing an additional 82 shares in the last quarter. Iron Financial LLC raised its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Iron Financial LLC now owns 4,811 shares of the company’s stock valued at $621,000 after purchasing an additional 87 shares in the last quarter. Aries Wealth Management raised its position in shares of Johnson & Johnson by 0.7% in the 4th quarter. Aries Wealth Management now owns 13,897 shares of the company’s stock valued at $1,793,000 after purchasing an additional 102 shares in the last quarter. Finally, Northside Capital Management LLC raised its position in shares of Johnson & Johnson by 1.0% in the 4th quarter. Northside Capital Management LLC now owns 10,903 shares of the company’s stock valued at $1,407,000 after purchasing an additional 105 shares in the last quarter. 67.32% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE JNJ opened at $136.52 on Tuesday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $366.27 billion, a PE ratio of 16.69, a PEG ratio of 2.08 and a beta of 0.68.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. During the same period in the previous year, the business earned $1.74 EPS. The business’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 8.58 EPS for the current year.
Johnson & Johnson announced that its Board of Directors has authorized a share buyback plan on Monday, December 17th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to purchase up to 1.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.
A number of equities analysts have issued reports on JNJ shares. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Morgan Stanley cut their target price on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $152.00 target price (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Barclays reaffirmed an “equal weight” rating and issued a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Finally, Citigroup cut their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 2nd. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $143.58.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://macondaily.com/2019/04/16/johnson-johnson-jnj-position-reduced-by-wendell-david-associates-inc.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.